On 17 March 2026, Alloy Therapeutics announced a multi-year agreement giving AbbVie access to its ATX-Gx-based antibody ...

AbbVie Inc. (NYSE:ABBV) is included among the 15 Dividend Stocks to Buy for Steady Income. On March 17, Alloy Therapeutics announced an agreement with AbbVie Inc. (NYSE:ABBV) to develop a new antibody ...

In the latest trading session, AbbVie (ABBV) closed at $206.23, marking a -1.01% move from the previous day. This change lagged the S&P 500's 0.28% loss on the day. On the other hand, the Dow ...

AbbVie (ABBV) has been under pressure recently, with the share price showing a 5.2% decline over the past day and an 8.5% drop over the past week, closing at US$208.34. Short term weakness has also ...

AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson’s Icotyde, the first oral IL-23 inhibitor on the market. This ...

The expansion is expected to create 300 new jobs, including positions for engineers, scientists, manufacturing operators and lab technicians.

The MAD portion of the study enrolled a total of 76 participants.

The company's ability to hold off generic competitors long enough to develop a pair of replacement drugs for Humira that are ...

AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a ...

AbbVie ABBV stock slipped below its 50-day simple moving average (SMA) on March 13, after consistently trading above it since mid-Feb. However, the stock has remained comfortably above its 200-day ...

After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis (PsA). | After ...

AbbVie Inc. ABBV shares are trading lower on Monday. The U.S. drug maker shared topline results from a Phase 1 study of ...